Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 9.56
-0.16 (-1.65%)
Aug 13, 2026, 5:23 PM CET
Xbrane Biopharma AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -75.88 | - | - | -322.03 | -172.51 | -188.38 |
Depreciation & Amortization | - | 21.14 | 35.95 | - | - | - |
Other Adjustments | -136.74 | -147.99 | -110.13 | 34.51 | 9.33 | 7.18 |
Change in Receivables | 37.22 | 70.03 | -4.56 | -85.13 | 1.7 | -61.09 |
Changes in Inventories | 10.95 | 48.98 | -166 | -56.6 | -50.26 | - |
Changes in Accounts Payable | -208.85 | -368.78 | 212.82 | 22.57 | 17.83 | 22.67 |
Changes in Income Taxes Payable | -2.32 | -2.23 | -11.59 | - | - | - |
Changes in Other Operating Activities | - | -0.51 | -0.44 | -0.65 | -9.88 | -10.4 |
Operating Cash Flow | -190.55 | -250.69 | -133.73 | -406.68 | -193.92 | -219.61 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | -0.5 | -6.79 | -11.62 | -27.68 |
Purchases of Intangible Assets | -126.55 | -139.64 | -51.75 | -9.98 | -48.51 | -49.67 |
Other Investing Activities | 102.5 | 102.5 | - | - | - | - |
Investing Cash Flow | -24.05 | -37.14 | -52.25 | -16.77 | -60.13 | -77.35 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | 57.6 | 77.6 | 70 | 225 | - | - |
Long-Term Debt Repaid | -20 | -43.5 | -112.5 | -20.83 | - | - |
Net Long-Term Debt Issued (Repaid) | 37.6 | 34.1 | -42.5 | 204.17 | - | - |
Issuance of Common Stock | 240 | 240 | 337.24 | 120.02 | 170.55 | 380.87 |
Net Common Stock Issued (Repurchased) | 240 | 240 | 337.24 | 120.02 | 170.55 | 380.87 |
Other Financing Activities | -15.26 | -18.5 | -51.12 | -25.49 | -21.69 | -32.03 |
Financing Cash Flow | 262.34 | 255.61 | 243.62 | 298.7 | 148.86 | 349.37 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -11.07 | -6.05 | 0.84 | -4.49 | 4.05 | 1.39 |
Net Cash Flow | 47.74 | -32.23 | 57.65 | -124.75 | -105.18 | 52.41 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -190.55 | -250.69 | -134.23 | -413.47 | -205.53 | -247.29 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -249.23% | -164.55% | -90.64% | -173.20% | -356.72% | -2309.16% |
Free Cash Flow Per Share | -0.17 | -15.25 | -8.17 | -87.29 | -1004.76 | -1310.16 |
Levered Free Cash Flow | -56.62 | -140.05 | -238.47 | -225.47 | -226.44 | -203.78 |
Unlevered Free Cash Flow | -268.67 | -331.08 | -35.66 | -338.18 | -206.58 | -191.87 |